NASDAQ:MLTX MoonLake Immunotherapeutics Q3 2024 Earnings Report $53.32 +0.40 (+0.76%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$53.08 -0.24 (-0.45%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast MoonLake Immunotherapeutics EPS ResultsActual EPS-$0.56Consensus EPS -$0.44Beat/MissMissed by -$0.12One Year Ago EPS-$0.18MoonLake Immunotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoonLake Immunotherapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time7:00AM ETUpcoming EarningsMoonLake Immunotherapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Tuesday, August 5, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MoonLake Immunotherapeutics Earnings HeadlinesMoonLake Immunotherapeutics Updates on Phase 3 VELA Program and Financial Results for Q2 20251 hour ago | quiverquant.comQMoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update1 hour ago | globenewswire.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 5 at 2:00 AM | Brownstone Research (Ad)Analysts Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $73.14August 3 at 2:47 AM | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Analysts at Rothschild & Co RedburnJuly 29, 2025 | americanbankingnews.comMoonLake initiated with a Neutral at Rothschild & Co RedburnJuly 28, 2025 | msn.comSee More MoonLake Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email. Email Address About MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.View MoonLake Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead? Upcoming Earnings Fortinet (8/6/2025)Airbnb (8/6/2025)DoorDash (8/6/2025)AppLovin (8/6/2025)Energy Transfer (8/6/2025)Sony (8/6/2025)Manulife Financial (8/6/2025)Novo Nordisk A/S (8/6/2025)Realty Income (8/6/2025)Brookfield Asset Management (8/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
